Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD1119 SAD in Healthy Participants
NCT07042594Phase 1Active, not recruiting
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in thromboembolic disease comparing RBD1119 SAD experimental group with Placebo SAD group (2 arms). Primary endpoint: Treatment Related Adverse Events. Started Aug 2025; status: active, not recruiting.
02
Drugs
RBD1119
03
Conditions
thromboembolic disease
Beyond the preview
Go deeper on NCT07042594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07042594.